Advertisement
Screener

SUTRO BIOPHARMA, INC. (STRO) ROI

SUTRO BIOPHARMA, INC. ROI

Return on investment (ROI), also called return on invested capital, is the profit a company earns for every dollar of long-term capital from both lenders and shareholders, shown as a percentage. It is net income divided by long-term debt plus shareholder equity, and the table shows both amounts. Because debt is included in the base, ROI does not rise just because a company replaces equity with borrowing, which sets it apart from ROE. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • SUTRO BIOPHARMA, INC. roi for fiscal 2023 was -69.48%, a change of -18.39% from fiscal 2022.
  • SUTRO BIOPHARMA, INC. roi for fiscal 2022 was -51.09%, a change of -13.08% from fiscal 2021.
  • SUTRO BIOPHARMA, INC. roi for fiscal 2021 was -38.01%.
Available history
2021-12-31 to 2023-12-31
Data captured

Historical ROI

DateROINet income 12 monthNet income 3 monthDebt plus equity
2023-12-31-69.48%-$106.79M$30.86M$153.71M
2022-12-31-51.09%-$119.2M-$34.59M$233.32M
2021-12-31-38.01%-$105.54M-$38.13M$277.68M

Annual ROI

DateROINet income 12 monthDebt plus equity
2023-12-31-69.48%-$106.79M$153.71M
2022-12-31-51.09%-$119.2M$233.32M
2021-12-31-38.01%-$105.54M$277.68M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Invivyd, Inc. (IVVD)United States$0.270B-2.42
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87